抗体药物偶联物在淋巴恶性肿瘤和多发性骨髓瘤临床试验中的应用。
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.
机构信息
Department of Medicine, Lincoln Medical Center, Bronx, NY, USA.
Department of Oncology, The First affiliated Hospital of Zhengzhou University, Zhengzhou, China.
出版信息
J Hematol Oncol. 2019 Sep 10;12(1):94. doi: 10.1186/s13045-019-0786-6.
Antibody-drug conjugates (ADC) represent a distinct family of chemoimmunotherapy agents. ADCs are composed of monoclonal antibodies conjugated to cytotoxic payloads via specialized chemical linkers. ADCs therefore combine the immune therapy with targeted chemotherapy. Due to the distinct biomarkers associated with lymphocytes and plasma cells, ADCs have emerged as a promising treatment option for lymphoid malignancies and multiple myeloma. Several ADCs have been approved for clinical applications: brentuximab vedotin, inotuzumab ozogamicin, moxetumomab pasudotox, and polatuzumab vedotin. More novel ADCs are under clinical development. In this article, we summarized the general principles for ADC design, and updated novel ADCs under various stages of clinical trials for lymphoid malignancies and multiple myeloma.
抗体药物偶联物 (ADC) 代表了一类独特的化疗免疫治疗药物。ADC 由单克隆抗体通过特殊的化学连接子与细胞毒性有效载荷偶联而成。因此，ADC 将免疫疗法与靶向化疗结合在一起。由于与淋巴细胞和浆细胞相关的独特生物标志物，ADC 已成为治疗淋巴恶性肿瘤和多发性骨髓瘤的一种有前途的治疗选择。几种 ADC 已被批准用于临床应用： Brentuximab vedotin、Inotuzumab ozogamicin、Moxetumomab pasudotox 和 Polatuzumab vedotin。更多新型 ADC 正在临床开发中。在本文中，我们总结了 ADC 设计的一般原则，并更新了处于不同临床试验阶段的用于治疗淋巴恶性肿瘤和多发性骨髓瘤的新型 ADC。
Zotero 插件